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Proteomics Proﬁling and Risk of New-Onset Atrial Fibrillation:
Framingham Heart Study
Darae Ko, MD, MSc; Mark D. Benson, MD, PhD; Debby Ngo, MD; Qiong Yang, PhD; Martin G. Larson, SD; Thomas J. Wang, MD;
Ludovic Trinquart, PhD; David D. McManus, MD, ScM; Steven A. Lubitz, MD, MPH; Patrick T. Ellinor, MD, PhD; Ramachandran S. Vasan, MD;
Robert E. Gerszten, MD; Emelia J. Benjamin, MD, ScM; Honghuang Lin, PhD
Background-—Prior studies relating proteomics markers to incident AF screened for limited numbers of proteins.
Methods and Results-—We performed proteomics assays among participants from the Framingham Heart Study Offspring attending
their ﬁfth examination. Plasma protein levels (n=1373) weremeasured by the SOMAscan proteomic proﬁling platform.We used robust
inference for the Cox proportional hazardsmodel to relate each protein level with incident AF. In addition, we examined the association
between AF-related genetic loci and levels of proteins associated with AF. Our study included 1885 participants (mean age
5510 years, 54% women) who had proteomic proﬁles measured. A total of 349 participants developed AF during follow-up (mean
follow-up 18.3 years). We observed that 8 proteins were signiﬁcantly associated with incident AF after adjusting for age, sex, technical
covariates, and correction for multiple testing (P<0.05/1373=3.69105). After additional adjustments for clinical factors associated
with AF, ADAMTS13andN-terminal pro-B-type natriuretic peptide remained signiﬁcantly associatedwith the risk of incident AF (hazard
ratio, 0.78; 95% CI, 0.70–0.88; and 1.44; 95%CI, 1.22–1.70, respectively; P<3.69105 for both). None of the 8 proteinswere encoded
by genes at AF-related genetic loci previously identiﬁed by genome-wide association studies.
Conclusions-—We identiﬁed 8 proteins associated with risk of incident AF after adjustment for age and sex; 2 proteins were
associated with AF after adjustment for AF risk factors. Future studies are needed to replicate our ﬁndings, identify whether the
markers are mechanistically related to AF development, and whether they are clinically useful for identiﬁcation of future AF risk.
( J Am Heart Assoc. 2019;8:e010976. DOI: 10.1161/JAHA.118.010976.)
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A pproximately 1 in 3 whites and 1 in 5 blacks will developatrial ﬁbrillation (AF) in their lifetime.1–3 The risk of AF
increases with advancing age, European ancestry, smoking,
higher height, weight, and blood pressure, antihypertensive
medication use, diabetes mellitus, and history of myocardial
infarction and heart failure.4 Independent of traditional clinical
factors, various biomarkers have been identiﬁed in relation to
the risk of incident AF including markers of myocardial
necrosis,5–7 myocardial stress,7–13 inﬂammation,7,14–16 oxida-
tive stress,17 and mineral metabolism.18,19 Identiﬁcation of
novel biomarkers may advance our understanding of disease
mechanisms, enhance opportunities for risk prediction, and
potentially provide new therapeutic targets for AF.
Proteomic proﬁling enables systematic high-throughput
analysis of proteins and holds the promise to substantially
accelerate novel biomarker discovery. Relatively unbiased
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proteomics approaches have the advantage of allowing simul-
taneous screening for large numbers of proteins involved in
different biological pathways. Recently, 2 longitudinal cohort
studies have reported proteomic proﬁling and the risk of new-
onset AF.13,14 The ﬁrst study used a proximity extension assay
to screen 92 proteins in community-based cohorts of older
adults in Sweden and identiﬁed 7 proteins that were associated
with incident AF after adjustment for age and sex.13 The second
study focused on 75 inﬂammatory marker proteins identiﬁed
from proximity extension assays, none of which were associ-
ated with new-onset AF after age and sex adjustment.14 In our
current study, we report the use of single-stranded DNA-based
aptamers as afﬁnity reagents to screen for 1373 proteins and
identify novel biomarkers that are associated with risk of
incident AF in a prospective cohort study.
Methods
Data Sharing
The results of proteomic assay for all 1373 proteins measured
in the Framingham Heart Study are available in the database
of Genotypes and Phenotypes.20 Additional results and
analyses not shown in the article are available from the
authors upon request. The details of the commercially
available aptamer-based proteomics assay are included in
the article. Noncommercial study materials are available to
other researchers for purposes of reproducing the results or
replicating the procedure, as respective Institutional Review
Board and Material Transfer Agreements permit.
Study Samples
The Framingham Heart Study is a community-based cohort
initiated in 1948. The Framingham Offspring cohort (Second
Generation) was recruited in 1971. They are the offspring and
the spouses of the offspring of the Original cohort.21 The
present study focused on 1885 Offspring cohort participants
who attended the ﬁfth examination (1991–1995) and com-
pleted an assessment of proteomics proﬁling. Twenty-eight
individuals with AF at baseline were excluded after proteomics
proﬁling. All participants gave written informed consent. The
study was approved by the Institutional Review Boards of
Boston University Medical Center, Massachusetts General
Hospital, and Beth Israel Deaconess Medical Center. All
aspects of the study were performed in compliance with
relevant guidelines and regulations.
Covariate Assessments
Current smoking was deﬁned as smoking ≥1 cigarettes per
day within 1 year preceding the Framingham Heart Study
visit, similar to our previously studies.1 Systolic and diastolic
blood pressures were measured twice with subjects in the
seated position. Participants were classiﬁed as having
diabetes mellitus if their blood glucose was ≥200 mg/dL or
fasting glucose was ≥126 mg/dL or if they were using insulin
or oral hypoglycemic medications.22 A panel of 3 physicians
determined myocardial infarction and heart failure based on
the criteria used previously.23
AF Ascertainment
The AF status was ascertained through multiple sources in the
Framingham Heart Study. A 12-lead ECG was conducted on
each participant during clinic visits scheduled every 4 to
8 years. The cardiovascular history was also solicited during
surveillance interviews biennially,24,25 and from hospitaliza-
tions related to cardiovascular disease and clinician visits. All
ECGs, including the Framingham Heart Study ECG, and other
electrocardiographic data (ie, Holter monitoring) performed
for clinical reasons, were reviewed by at least 2 cardiologists
to adjudicate incident AF. Participants with prevalent AF at
baseline were excluded from the analysis.
Proteomics Proﬁling
Details of proteomics proﬁling have been described previ-
ously.26,27 In brief, citrate-plasma was obtained from blood
samples that were collected during clinical visits and stored at
80°C.28 Protein levels in the plasma samples were
measured by the SOMAscan platform, which uses single-
stranded DNA-based aptamers to capture conformational
protein epitopes.29 The technology has been validated in a
study of cardiovascular disease.26,30 Samples were assayed in
2 batches (n=821 and 1092, respectively). The measurements
were loge transformed and standardized to mean=0 and SD=1
in each batch separately after adjusting for age and sex. The
distribution of the signiﬁcant loge-transformed protein
Clinical Perspective
What Is New?
• In a community-based prospective cohort study, we iden-
tiﬁed novel biomarkers associated with incident atrial
ﬁbrillation after screening for 1373 proteins using pro-
teomics proﬁling.
• Both ADAMTS13 and N-terminal pro-B-type natriuretic
peptide remained signiﬁcantly associated with incident
atrial ﬁbrillation after multivariable adjustment and Bonfer-
roni correction.
What Are the Clinical Implications?
• Identiﬁcation of ADAMTS13 may suggest a novel pathophysio-
logical mechanism or a risk marker for atrial ﬁbrillation.
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concentrations is shown in Table S1. We previously published
median intra-assay coefﬁcient of correlation of 8.2% and
interassay coefﬁcient of correlation of 7.8% using the same
assay in the Framingham Heart Study.26 A total of 1373
proteins were assayed.
Statistical Analyses
Baseline characteristics were described as meanSD for
continuous covariates and counts (%) for dichotomous
covariates. Our primary analysis tested the association
between protein level and incident AF. Cox proportional
hazards regression models with clustering on pedigrees and
robust sandwich estimators were used to relate each protein
level to incident AF (censored at the last follow-up time or
death). The analysis was adjusted for age and sex. In addition,
we conducted a multivariable analysis adjusted for previously
reported AF risk factors,4 including smoking, height, weight,
systolic blood pressure, diastolic blood pressure, antihyper-
tensive treatment, diabetes mellitus, prevalent myocardial
infarction, and prevalent heart failure. In an exploratory
analysis, we performed a forward selection analysis by ﬁrst
adjusting for height and weight, followed by systolic and
diastolic blood pressures, and ﬁnally by adjusting for the rest
of covariates. Given the difference in the protein proﬁling
batches, the 2 batches were analyzed separately, and the
summary results from both batches were meta-analyzed using
the inverse-variance weighting approach. Bonferroni correc-
tion was used to correct for multiple testing; we considered
P<0.05/1373=3.649105 statistically signiﬁcant.
Association With AF-Related Genetic Loci
We also examined the association between AF-related genetic
loci and the circulating proteins that were signiﬁcantly
associated with incident AF after age- and sex-adjustment,
and Bonferroni correction. The analysis was restricted to the
97 genetic loci that were previously reported to associate with
AF susceptibility by genome-wide association studies.31–34
Linear mixed effects regression models were used to test the
association between each genetic variant and protein levels,
in which protein levels were treated as the dependent
measures and genetic variants were treated as the predictors.
The analysis was adjusted for age, sex, and the family
structure in the Framingham Heart Study. We used Bonferroni
correction to account for multiple testing, and the signiﬁcance
was claimed if the P value of the association was >0.05/
(number of proteins997 single nucleotide polymorphisms).
Results
The descriptive characteristics of the 1885 participants are
provided in Table 1. The mean age of the sample was
5510 years and 54% were women. A total of 349 partic-
ipants developed new-onset AF during follow-up (mean follow-
up 18.3 years).
Association of Protein Levels With Incident AF
Table 2 reports 8 proteins that were signiﬁcantly associated
with incident AF after age and sex adjustment and correction
for multiple testing (P<3.649105). The concentration distri-
bution of these proteins is shown in Table S1. Six were
associated with decreased risk and 2 were associated with
increased risk of incident AF. Neural cell adhesion molecule 1
to 120-kDa isoform had the most signiﬁcant association. After
further adjusting for clinical factors associated with incident
AF, a disintegrin and metalloproteinase with thrombospondin
motifs 13 (ADAMTS13) protein and N-terminal pro-B-type
natriuretic peptide remained signiﬁcantly associated with risk
of incident AF. In exploratory analyses with forward covariate
selection, the remaining 6 proteins were no longer signiﬁcant
after adjusting for weight and height (Table S2).
Among the 349 incident AF/atrial ﬂutter cases in our
study, 39 participants had atrial ﬂutter. We performed a
performed a sensitivity analysis by excluding the atrial ﬂutter
sample, and the association remained largely the same
(Table S3).
Association of AF-Related Genetic Variants With
Protein Levels
We also examined whether any of the 8 circulating proteins
that were signiﬁcantly associated with incident AF were also
associated with any of the reported 97 AF-related genetic
Table 1. Baseline Characteristics of Study Sample by
Whether or Not Participants Developed Incident AF
Variable
AF Cases
(n=349)
Referents
(N=1536)
Age, y 619 5410
Women 144 (41.3%) 872 (56.8%)
Height, cm 16910 1679
Weight, kg 8217 7616
Current smoker 52 (14.9%) 315 (20.5%)
Systolic blood pressure, mm Hg 13420 12518
Diastolic blood pressure, mm Hg 7510 7410
Antihypertensive medication use 117 (33.7%) 241 (15.8%)
Diabetes mellitus 49 (14.0%) 94 (6.1%)
Prevalent heart failure 1 (0.3%) 4 (0.3%)
Prevalent myocardial infarction 19 (5.4%) 31 (2.0%)
AF indicates, atrial ﬁbrillation.
Values are n (%), or meanSD.
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loci.31–33 None of the 776 associations (8 proteins997 single
nucleotide polymorphisms) reached the signiﬁcance cutoff
(P<6.449105). The top 20 associations out of 776 are listed
in Table S4. In addition, none of the 8 proteins were encoded
by the AF-related genetic loci.
Discussion
In our community-based prospective cohort study, we tested
1373 plasma proteins and observed that 8 proteins were
associated with risk of incident AF after adjustment for age
and sex. The currently known biological functions of the 8
proteins are described in Table S5. Both ADAMTS13 and N-
terminal pro-B-type natriuretic peptide remained signiﬁcantly
associated with incident AF after multivariable adjustment
and Bonferroni correction.
N-terminal pro-B-type natriuretic peptide, a marker of
ventricular remodeling, previously has been reported to be
associated with incident AF by multiple prospective popula-
tion-based studies.8–13 ADAMTS13 is a von Willebrand factor
protease, and its deﬁciency is found in thrombotic thrombo-
cytopenic purpura. Previous case–control studies have shown
that lower ADAMTS13 protein level was associated with
chronic and paroxysmal AF.35 In addition, higher von Wille-
brand factor/ADAMTS13 ratio was signiﬁcantly associated
with chronic AF and left atrial remodeling35 and higher von
Willebrand factor/ADAMTS13 ratio drawn 24 hours after
cardioversion was associated with higher risk of AF recur-
rence.36 It is possible that atrial remodeling, which promotes
AF, also promotes prothrombotic milieu; ADAMTS13 may be a
marker of the prothrombotic environment. Alternatively, the
prothrombotic dysregulation as represented by decreased
levels of ADAMTS13 may directly promote AF formation.
Interestingly, prior prospective cohort studies have shown
that ADAMTS13 is associated with incident myocardial
infarction and ischemic stroke.37,38 Whether ADAMTS13
dysregulation leads to the thrombotic events or AF was
unrecognized in these studies merits further investigation.
Of the remaining 6 proteins that were signiﬁcantly
associated with incident AF after adjusting for age and sex,
BMPR1A and angiopoietin-2 may be of particular interest in
cardiovascular research. BMP ligands and receptors including
BMPR1A are essential for embryonic and cardiac develop-
ment, and mutations in the proteins are associated with
pulmonary arterial hypertension and hereditary hemorrhagic
telangiectasia.39 In addition, recent work has shown that the
BMP signaling pathway plays an important role in the
development of atherosclerosis and myocardial remodel-
ing.39–41 Angiopoietins are endothelial growth factors that
regulate angiogenesis and vascular function. Increased levels
of angiopoietin-2 have been observed in patients with
myocardial infarction,42 heart failure,43 peripheral artery
disease,44 and end-stage renal disease.45 The results of our
study may suggest a novel downstream effect of BMPR1A and
angiopoietin-2.
To date, there have been 2 longitudinal cohort studies that
have used the proteomic approach to study protein biomarkers
associated with incident AF.13,14 The Swedish cohort study13
used the Olink Proseek Multiplex Cardiovascular 96996 kit to
screen for 92 proteins. The study sample included 2
community-based samples from Uppsala, Sweden: the
Prospective Investigation of the Vasculature in Uppsala
Table 2. Protein Biomarkers Associated With Incident AF
Protein
Age and Sex Adjusted Multivariable Adjusted*
HR (95% CI)† P Value‡ HR (95% CI)† P Value‡
NCAM-120 0.74 (0.67–0.82) 4.299108 0.84 (0.74–0.95) 5.209103
WFIKKN2 (WFKN2) 0.75 (0.67–0.83) 1.589107 0.86 (0.76–0.96) 1.099102
Ntrk3 (TrkC) 0.75 (0.68–0.84) 6.069107 0.82 (0.73–0.92) 9.909104
EGFR (ERBB, ERBB1) 0.75 (0.67–0.84) 1.189106 0.82 (0.72–0.93) 1.489103
ADAMTS13 (ATS13) 0.77 (0.69–0.86) 2.239106 0.78 (0.70–0.88) 1.759105
Angiopoietin-2 1.27 (1.15–1.41) 3.099106 1.16 (1.04–1.31) 1.099102
NT-proBNP§ 1.44 (1.24–1.69) 4.179106 1.44 (1.22–1.70) 1.469105
BMPR1A 0.75 (0.66–0.85) 5.939106 0.82 (0.72–0.93) 2.329103
ADAMTS13 indicates a disintegrin and metalloproteinase with thrombospondin motifs 13; AF, atrial ﬁbrillation; BMPR1A, bone morphogenetic protein receptor type-1A; EGFR, epidermal
growth factor receptor; HR, hazard ratio; NCAM-120, neural cell adhesion molecule 1, 120 kDa isoform; NT-proBNP, N-terminal pro-brain natriuretic peptide; TrkC, tropomyosin receptor
kinase C; WFKN2, WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2.
*Covariates include smoking, height, weight, systolic blood pressure, diastolic blood pressure, antihypertensive treatment, diabetes mellitus, prevalent myocardial infarction, and prevalent
heart failure.
†Hazard ratio expressed per standard deviation of the protein concentration.
‡Signiﬁcance level of P<0.05/1373=3.649105.
§This protein was only measured in 1075 samples because of differences in SOMAscan platform between Batch 1 and Batch 2.
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Seniors (PIVUS) and the Uppsala Longitudinal Study of Adult
Men (ULSAM) cohorts. In PIVUS (mean age 70 years, 51%
women), there were 148 incident AF cases among 978
participants during the median follow-up of 10 years. In
ULSAM (mean age 77.5 years, 0% women), there were 123
incident AF cases among 725 participants during the median
follow-up of 7.9 years. In the combined analysis of both
cohorts, the study found 7 proteins to be associated with the
risk of incident AF after age and sex adjustment. Two of the 7
proteins, N-terminal pro-B-type natriuretic peptide and IL-6,
remained signiﬁcantly associated after multivariable adjust-
ment in the Swedish cohort study (Table S6). The second
cohort study used a community-based sample from Bruneck,
Italy14 (mean age 58.8 years, 49% women) to screen specif-
ically for inﬂammatory biomarkers using the Olink Proseek
Multiplex Cardiovascular 96996 and the Proseek Multiple
Inﬂammation I 96996 kits. There were 117 new AF cases
among 880 participants during 20-year follow-up. The Italian
study reported the results of 75 inﬂammatory biomarkers
including ﬁbroblast growth factor-23, IL-6, fatty acid binding
protein 4, none of which were associated with AF after age
and sex adjustment in their sample (Table S6). In our study,
we did not ﬁnd evidence of nominally or Bonferroni corrected
statistically signiﬁcant association for ﬁbroblast growth
factor-23 or IL-6.
In our study, we did not ﬁnd evidence of a nominally or
Bonferroni corrected statistically signiﬁcant association for
previously reported AF-related proteins from nonproteomic
immunoassays including troponin,5–7 C-reactive protein,11,12,14
vascular cell adhesion molecule 1,14 ﬁbroblast growth factor-
23,18,19 and IL-646 (Table S6). Various factors could have
contributed to the discrepancy. In the current study, we tested
1373 proteins in a modest-size cohort; modest power and
accounting for multiple testing may have led to false-negative
ﬁndings. Differences in the characteristics of the cohorts could
be another important factor. We measured the proteins levels
at a relatively young age (5510 years versus 70 and 77 years
for the 2 cohorts in the Swedish study13) and had a relatively
long follow-up period (mean 18.3 years versus median 7.9 and
10 years for the 2 cohorts in the Swedish study13). Previous
studies measured protein levels using targeted single protein
immunoassays or proximity extension assay; it may be
challenging to compare them directly with the current study
because of differences in sensitivity and speciﬁcity of the
different assays. Further investigation is necessary to under-
stand the variations between different assays in capturing
different protein isoforms.
Our study has several limitations. We combined atrial
ﬂutter and AF despite their distinct electrophysiological
differences in disease mechanisms. We also acknowledge
that we were limited in our ability to correctly classify
paroxysmal versus persistent AF, and hence we did not
distinguish AF subtypes in our AF outcome. New-onset AF
may have been underreported in our study because we did not
have continuous ECG monitoring, and AF is often paroxysmal
and asymptomatic. Protein levels were measured at a single
time point, and therefore we were unable to test whether
changes in protein concentrations over time are associated
with development of new-onset AF. The lack of association
between the protein levels and the AF-related genetic variants
may be in part because of lack of power and false-negative
ﬁndings because of correction for multiple testing but also
because of the fact that the proteins are likely regulated by
multiple genetic loci. Another possible reason may include the
heterogeneous nature of AF mechanisms such as genetic
predisposition to AF, atrial ﬁbrosis, prothombotic dysregula-
tion, and other mechanisms.47 In addition, the fact that the 8
proteins were not encoded by the AF-related genetic variants
suggests that these proteins might not be causal to AF
pathogenesis. For instance, they might be biomarkers for
underlying AF mechanisms or subclinical AF. Future investi-
gation such as a gene-annotation approach would be helpful
to test our proteins on a genomic level and better understand
the connection between genetic loci and protein concentra-
tion.48
Our study cohort was predominantly of European ancestry,
and our results may not be generalizable to other races or
ethnicities. In addition, as with any high-throughput “-omics”
studies, batch effects may limit reproducibility of our results.
Finally, although our proteomics platform is the one of the
largest to date in cardiovascular research, we were only able
to detect proteins that were included in the platform.
In conclusion, in our proteomics screening of 1373
proteins in a longitudinal cohort study, we found 8 proteins
to be associated with the risk of incident AF after adjustment
for age and sex, and 2 proteins were associated with
multivariable adjustment. Further studies are needed to
replicate our ﬁndings and identify the pathophysiological
mechanisms underlying the reported associations and their
clinical implications.
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Table S1. Distribution of the significant loge-transformed protein concentration among samples. 
  
Protein Batch 1† Batch 2† 
AF cases Referents AF cases Referents 
NCAM-120 8.30±0.20 8.30±0.20 9.19±0.21 9.25±0.20 
WFKN2 7.79±0.28 7.82±0.26 8.33±0.28 8.43±0.29 
TrkC 7.35±0.21 7.39±0.22 7.77±0.20 7.83±0.23 
ERBB1 9.83±0.16 9.90±0.14 10.14±0.15 10.21±0.15 
ADAMTS13 7.97±0.20 8.05±0.23 8.25±0.26 8.38±0.25 
Angiopoietin-2 6.24±0.26 6.17±0.24 4.60±0.29 4.56±0.24 
NT-proBNP§   8.37±0.78 8.06±0.73 
BMPR1A 5.86±0.29 5.92±0.35 6.27±0.28 6.35±0.26 
 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin motifs 13; BMPR1A: bone 
morphogenetic protein receptor type-1A; NCAM-120: Neural cell adhesion molecule 1, 120 kDa 
isoform; NT-proBNP: N-terminal pro-brain natriuretic peptide; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; TrkC: tropomyosin receptor kinase C; WFKN2: WAP, Kazal, immunoglobulin, 
Kunitz and NTR domain-containing protein 2  
 
†Data are expressed as mean ± SD  
§This protein was only measured in Batch 2 samples due to differences in SOMAscan platform between 
Batch 1 and Batch 2. 
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Table S2. Stepwise forward selection analysis for the 8 proteins significantly associated incident AF after age and sex adjustment. 
 
Protein 
Adjusted for age and sex 
Adjusted for age and sex, 
weight, height 
Adjusted for age and sex, 
weight, height, SBP, DBP 
Multivariable-adjusted 
model* 
HR (95% CI)† p value‡ HR (95% CI)† p value‡ HR (95% CI)† p value‡ HR (95% CI)† p value‡ 
NCAM-120 0.74 (0.67-0.82) 4.29x10-8 0.8 (0.71-0.89) 1.30x10-4 0.81 (0.72-0.91) 4.83x10-4 0.84 (0.74-0.95) 5.20x10-3 
WFKN2 0.75 (0.67-0.83) 1.58x10-7 0.81 (0.72-0.91) 3.27x10-4 0.83 (0.74-0.93) 1.62x10-3 0.86 (0.76-0.96) 1.09x10-2 
TrkC 0.75 (0.68-0.84) 6.06x10-7 0.8 (0.72-0.9) 2.19x10-4 0.81 (0.72-0.91) 3.81x10-4 0.82 (0.73-0.92) 9.90x10-4 
ERBB1 0.75 (0.67-0.84) 1.18x10-6 0.78 (0.7-0.88) 6.88x10-5 0.79 (0.7-0.89) 1.34x10-4 0.82 (0.72-0.93) 1.48x10-3 
ADAMTS13 0.77 (0.69-0.86) 2.23x10-6 0.77 (0.69-0.85) 1.70x10-6 0.78 (0.7-0.87) 9.18x10-6 0.78 (0.7-0.88) 1.75x10-5 
Angiopoietin-2 1.27 (1.15-1.41) 3.09x10-6 1.23 (1.11-1.37) 1.29x10-4 1.2 (1.07-1.34) 1.12x10-3 1.16 (1.04-1.31) 1.09x10-2 
NT-proBNP§ 1.44 (1.24-1.69) 4.17x10-6 1.53 (1.3-1.79) 1.51x10-7 1.51 (1.29-1.78) 5.40x10-7 1.44 (1.22-1.7) 1.46x10-5 
BMPR1A 0.75 (0.66-0.85) 5.93x10-6 0.79 (0.7-0.9) 2.44x10-4 0.8 (0.71-0.91) 7.01x10-4 0.82 (0.72-0.93) 2.32x10-3 
 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin motifs 13; BMPR1A: bone morphogenetic protein receptor type-1A; NCAM-
120: Neural cell adhesion molecule 1, 120 kDa isoform; NT-proBNP: N-terminal pro-brain natriuretic peptide; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; TrkC: tropomyosin receptor kinase C; WFKN2: WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2  
 
*Covariates include smoking, height, weight, systolic blood pressure, diastolic blood pressure, antihypertensive treatment, diabetes mellitus, 
prevalent myocardial infarction, and prevalent heart failure 
†Hazard ratio expressed per standard deviation of the protein concentration 
‡Significance level of p<0.05/1373=3.64x10-5 
§This protein was only measured in 1075 samples due to differences in SOMAscan platform between Batch 1 and Batch 2. 
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Table S3. Association of protein biomarkers with incident AF after excluding atrial flutter (n=39). 
 
Protein HR (95% CI)† p value 
NCAM-120 0.73 (0.65-0.82) 6.44x10-8 
WFKN2 0.76 (0.68-0.86) 4.04x10-6 
TrkC 0.75 (0.67-0.84) 1.06x10-6 
ERBB1 0.74 (0.66-0.84) 1.46x10-6 
ADAMTS13 0.76 (0.68-0.86) 4.99x10-6 
Angiopoietin-2 1.29 (1.17-1.44) 8.57x10-7 
NT-proBNP§ 1.51 (1.28-1.79) 1.47x10-6 
BMPR1A 0.75 (0.66-0.86) 2.38x10-5 
 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin motifs 13; BMPR1A: bone 
morphogenetic protein receptor type-1A; NCAM-120: Neural cell adhesion molecule 1, 120 kDa 
isoform; NT-proBNP: N-terminal pro-brain natriuretic peptide; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; TrkC: tropomyosin receptor kinase C; WFKN2: WAP, Kazal, immunoglobulin, 
Kunitz and NTR domain-containing protein 2  
 
†Hazard ratio expressed per standard deviation of the protein concentration 
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Table S4. Top 20 associations out of 776 (8 proteins * 97 SNPs) between the 8 proteins identified 
in the current study and the 97 previously reported AF-genetic loci. None of these associations 
reached the pre-defined statistical significance threshold (P<6.44x10-5). 
SNP Locus Protein name HR (95% CI)  P-value 
rs7508 8p22 ADAMTS13 0.89 (0.83-0.96) 3.37x10-3 
rs60212594 10q22.2 ADAMTS13 1.13 (1.03-1.24) 9.58x10-3 
rs62483627 7q22.3 ADAMTS13 1.11 (1.02-1.20) 1.28x10-2 
rs60212594 10q22.2 Angiopoietin-2 0.86 (0.78-0.94) 1.52x10-3 
rs11001667 10q22.3 BMPR1A 0.87 (0.79-0.96) 4.54x10-3 
rs242557 17q21.31 BMPR1A 1.11 (1.02-1.20) 1.04x10-2 
rs72700114 1q24.2 BMPR1A 1.19 (1.04-1.36) 1.29x10-2 
rs60212594 10q22.2 BMPR1A 1.12 (1.02-1.24) 1.64x10-2 
rs12298484 12q24.31 ERBB1 1.12 (1.05-1.20) 4.73x10-4 
rs7508 8p22 ERBB1 0.92 (0.86-0.98) 1.66x10-2 
rs7508 8p22 NCAM-120 0.90 (0.84-0.97) 7.10x10-3 
rs7978685 12q13.3 NT-proBNP 1.15 (1.05-1.27) 3.55x10-3 
rs6546620 2p23.3 NT-proBNP 1.15 (1.02-1.29) 1.88x10-2 
rs7789146 7q36.1 TrkC 1.12 (1.03-1.22) 1.17x10-2 
rs10760361 9q33.3 TrkC 0.91 (0.85-0.98) 1.28x10-2 
rs13191450 6q22.31 TrkC 1.09 (1.02-1.17) 1.60x10-2 
rs60212594 10q22.2 TrkC 1.12 (1.02-1.24) 1.79x10-2 
rs7508 8p22 TrkC   0.87 (0.80-0.94) 2.37x10-4 
rs949078 11q24.1 WFKN2 0.91 (0.84-0.98) 1.50x10-2 
rs10760361 9q33.3 WFKN2 0.92 (0.85-0.98) 1.60x10-2 
 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin motifs 13; BMPR1A: bone 
morphogenetic protein receptor type-1A; NCAM-120: Neural cell adhesion molecule 1, 120 kDa 
isoform; NT-proBNP: N-terminal pro-brain natriuretic peptide; TrkC: tropomyosin receptor kinase C; 
WFKN2: WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2  
 
*Significance level of p<0.05/(8 proteins * 97 SNPs) =6.44x10-5. None of them reached the significance 
cutoff.  
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Table S5. Biological functions of the 8 proteins associated with the risk of incident AF1,2 
Protein  Function 
NCAM-120 Immunoglobulin-like glycoprotein. Activates fibroblast growth factor receptor and 
induces neurite outgrowth. Over-expression in neuroblastoma cells. 
WFKN2 
(WFIKKN2) 
Multivalent protease-inhibitor. Inhibits growth differentiation factor and myostatin.   
TrkC (Ntrk3) One of tropomyosin receptor kinases that bind to neurotrophin-3, which in turn 
induces growth and differentiation of neuronal cells. Mutations in the gene 
associated with medulloblastoma, neuroblastoma, breast cancer, and other 
cancers.   
EGFR (ERBB1) Transmembrane glycoprotein kinase that acts as a receptor for epidermal growth 
factor. Mutations in the gene associated with different types of cancers. 
ADAMTS13 
(ATS13) 
Multivalent protein that cleaves von Willebrand Factor. Mutations in the gene are 
associated with thrombotic thrombocytopenic purpura.  
Angiopoietin-2 Inhibits angiopoietin-1 and endothelial TEK tyrosine kinase, thereby regulating 
angiogenesis and endothelial function.  
NT-proBNP Secreted by ventricular myocardium upon myocardial stretching and causes 
natriuresis, diuresis, vasodilation, and inhibition of the renin-angiotensin-
aldosterone system.  
BMPR1A Transmembrane serine/threonine kinase receptor that binds to the members of the 
TGF-β superfamily. Mutations in the gene are associated with pulmonary arterial 
hypertension and hereditary hemorrhagic telangiectasia.  
 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin motifs 13; BMPR1A: bone 
morphogenetic protein receptor type-1A; CI: confidence interval; EGFR: epidermal growth factor 
receptor; HR: hazard ratio; NCAM-120: Neural cell adhesion molecule 1, 120 kDa isoform; NT-proBNP: 
N-terminal pro-brain natriuretic peptide; TrkC: tropomyosin receptor kinase C; WFKN2: WAP, Kazal, 
immunoglobulin, Kunitz and NTR domain-containing protein 2  
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Table S6. Protein biomarkers associated with incident AF in prospective cohort studies. 
ProteinREF Type of assay Study sample 
HR (95% CI) p-value HR (95% CI) p-value 
Age-, sex-, ± race-adjusted Multivariable-adjusted 
NT-proBNP3 PEA PIVUS, ULSAM 1.57 (1.41-1.76) <0.0001* 1.57 (1.39-1.76) <0.0001* 
NT-proBNP Aptamer-based FHS 1.44 (1.24-1.69) <0.00001† 1.44 (1.22-1.70) 0.000015† 
NT-proBNP/BNP4 Immunoassay§ CHARGE-US NR NR 1.66 (1.56-1.76) <0.0001 
FGF-233 PEA PIVUS, ULSAM 1.26 (1.14-1.4) <0.0001* 1.18 (1.06-1.32) 0.0025 
FGF-235 PEA Bruneck, Italy 1.04 (0.80-1.36) 0.75 NR NR 
FGF-23 Aptamer-based FHS 0.95 (0.85-1.06) 0.052 0.93 (0.83-1.04) 0.18 
FGF-236 Immunoassay ARIC 1.31 (1.19-1.45) NR 1.07 (0.96-1.18) NR 
FGF-237 Immunoassay MESA 1.79 (1.45-2.21)‖ <0.001 1.41 (1.13-1.76)‖ 0.003 
FGF-237 Immunoassay CHS 1.31 (1.07-1.60)‖ 0.010 1.29 (1.05-1.60)‖ 0.018 
IL-63 PEA PIVUS, ULSAM 1.26 (1.13-1.4) <0.0001* 1.25 (1.11-1.4) 0.0001* 
IL-65 PEA Bruneck, Italy 1.19 (0.98-1.45) 0.08 NR NR 
IL-6 Aptamer-based FHS 0.99 (0.89-1.10) 0.85 0.96 (0.86-1.07) 0.44 
IL-68 Immunoassay FHS NR NR 1.08 (0.91-1.29) 0.36 
FABP43 PEA PIVUS, ULSAM 1.32 (1.16-1.5) <0.0001* 1.22 (1.05-1.43) 0.012 
FABP45 PEA Bruneck, Italy 1.41 (1.07-1.87) 0.02 NR NR 
GDF-153 PEA PIVUS, ULSAM 1.27 (1.13-1.44) 0.0001* 1.25 (1.09-1.44) 0.0018 
GDF-159 Immunoassay FHS 1.31 (1.14-1.49) <0.0001 1.15 (0.99-1.32) 0.061 
TIM-13 PEA PIVUS, ULSAM 1.26 (1.12-1.43) 0.0002* 1.23 (1.07-1.4) 0.0028 
AM3 PEA PIVUS, ULSAM 1.27 (1.11-1.44) 0.0004* 1.22 (1.06-1.4) 0.0044 
ST23 PEA PIVUS, ULSAM 1.05 (0.92-1.2) 0.44 1.08 (0.94-1.24) 0.27 
ST25 PEA Bruneck, Italy 1.19 (0.94-1.50) 0.14 NR NR 
ST29 Immunoassay FHS 1.06 (0.92-1.22) 0.39 1.02 (0.89-1.17) 0.76 
TnI Aptamer-based FHS 1.04 (0.93-1.16) 0.51 1.02 (0.91-1.14) 0.078 
hsTnI9 Immunoassay FHS 1.25 (1.13-1.37) <0.0001 1.18 (1.07-1.32) 0.002 
hsTnT10 Immunoassay ARIC 1.43 (1.37-1.51) <0.0001 1.32 (1.25-1.39) <0.0001 
hsTnT11 Immunoassay CHS 1.67 (1.52-1.83) NR 1.45 (1.32-1.59) NR 
CRP Aptamer-based FHS 1.10 (0.98-1.25) 0.11 0.94 (0.82-1.08) 0.38 
CRP4 Immunoassay CHARGE-US NR NR 1.18 (1.11-1.25) <0.0001 
hsCRP5 Immunoassay Bruneck, Italy 0.94 (0.77-1.15) 0.56 NR NR 
CRP12 Immunoassay FHS NR NR 1.25 (1.07-1.46) 0.004 
VCAM-1 Aptamer-based FHS 1.06 (0.94-1.19) 0.34 0.99 (0.87-1.11) 0.82 
VCAM-15 Immunoassay Bruneck, Italy 1.35 (1.12-1.63) 0.001 NR NR 
*Significance level of p-value <0.000588 (Bonferroni correction) 
†Significance level of p-value <0.000036 (Bonferroni correction)  
§”Immunoassay” refers to standard immunoassay of a single protein with significance level of p-value < 0.05 
‖HR per doubling of the protein level 
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ARIC: The Atherosclerosis Risk in Communities Study; AM: adrenomedullin; CHARGE-US: Cohorts for Heart and Aging Research in Genomic 
Epidemiology Consortium, which includes multiple international cohorts. CHARGE-US includes the US cohorts – FHS, ARIC, CHS; CHS: 
Cardiovascular Health Study; CI: confidence interval; CRP: C-reactive protein; IL-6: interleukin-6; FABP4: fatty acid binding protein 4; FGF-23: 
fibroblast growth factor 23; FHS: Framingham Heart Study; GDF-15: growth differentiation factor 15; HR: hazard ratio; hsTnI/T: high-sensitive 
troponin I/T; MESA: Multi-Ethnic Study of Atherosclerosis; NR: not reported; NT-proBNP: N-terminal pro-brain natriuretic peptide; PEA: proximity 
extension assay; PIVUS: The Prospective Investigation of the Vasculature in Uppsala Seniors study; TIM-1: T-cell immunoglobulin and mucin 
domain 1; ULSAM: Uppsala Longitudinal Study of Adult Men; VCAM-1:  vascular cell adhesion molecule 1; 
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